|
Genomic risk classification by the 70-gene signature and 21-gene assay in African American early-stage breast cancer patients. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Agendia |
Research Funding - Agendia |
|
|
Employment - Texas Oncology |
Stock and Other Ownership Interests - Texas Oncology |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Genentech; Merck |
|
|
|
Stock and Other Ownership Interests - Agendia |
Patents, Royalties, Other Intellectual Property - NXT Biologics |
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
No Relationships to Disclose |